Clinical Trial Update: A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant FOLFIRINOX and FDR-Gemcitabine with concurrent IMRT in pancreatic cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• FDR-Gemcitabine (Gemcitabine)
• FOLFIRINOX

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-08-08